Table 5. Cox regression multivariate analysis for overall survival.
| Variable | Significance (p-value) | Hazard ratio | 95% CI for Exp (B) | |
|---|---|---|---|---|
| Lower | Upper | |||
| Age ≥ 35 years | 0.370 | 0.625 | 0.223 | 1.748 |
| Mastectomy (vs BCS) | 0.256 | 0.554 | 0.200 | 1.534 |
| Stage III (vs Stage I & II) | 0.078 | 2.623 | 0.897 | 7.669 |
| TNBC (vs HR+ & HER2+) | 0.002 | 4.057 | 1.707 | 9.642 |
| Interval > 24 months | 0.002 | 0.252 | 0.105 | 0.603 |
| Recurrence site at LNs (vs breast & chest wall) | 0.052 | 2.518 | 0.993 | 6.382 |
| Adjuvant chemotherapy (vs no chemotherapy) | 0.035 | 2.367 | 1.064 | 5.268 |
CI, confidential interval; BCS, breast conserving surgery; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, Triple negative breast cancer; LN, lymphnode